Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [1]. Core Views - The clinical CRO industry is experiencing a recovery, with increasing demand driven by the global rise in innovative drug financing and the expansion of clinical trial outsourcing. The company is expected to benefit from this trend, with a significant increase in new orders and market share [8]. - The company has established itself as a leader in the clinical CRO market in China, with its market share rising from 8.7% in 2019 to 12.8% in 2023. This growth is attributed to the optimization of supply and the company's strong competitive position [8]. - The company's revenue and profit forecasts indicate a recovery, with expected revenues of 71.29 billion yuan in 2025, 80.19 billion yuan in 2026, and 93.27 billion yuan in 2027, alongside a substantial increase in net profit [8]. Summary by Sections Company Overview - Founded in 2004, the company has grown to become a leading clinical CRO in China, providing comprehensive services for the biopharmaceutical industry through self-built and acquired networks [14]. - The company's ownership structure is stable, with key founders holding significant shares and a management team experienced in top-tier biopharmaceutical companies [15]. Financial Analysis - The company has experienced revenue growth from 254 million yuan in 2012 to 6.603 billion yuan in 2024, with a compound annual growth rate (CAGR) of 28.5%. However, growth has slowed in 2023 and 2024 due to market conditions [19]. - The company’s gross margin has faced pressure, but a recovery is anticipated in 2026 as low-priced orders are cleared and new orders increase [22]. Industry Outlook - The global demand for CRO services is expected to grow, with the penetration rate of outsourced pharmaceutical R&D projected to exceed 50% by 2024 and reach approximately 65% by 2033 [43]. - The number of CRO companies in China has decreased significantly due to market consolidation, enhancing the competitive landscape for leading firms like the company [52]. Business Segments - The company operates primarily in two segments: Clinical Trial Technical Services (CTS) and Clinical Trial Related Services and Laboratory Services. CTS is the cornerstone of the business, covering all phases of clinical trials [54]. - The company has a strong international presence, with operations in 33 countries and a growing number of overseas projects, reflecting its commitment to global expansion [63].